Skip to main content
Ibrutinib + venetoclax: High-risk features don’t lessen CLL response
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Ibrutinib + venetoclax: High-risk features don’t lessen CLL response
User login
Username
Password
Reset your password
Concept
Lead
score
Chronic Lymphocytic Leukemia
1
1
Targeted Cancer Therapy
0
0.77
Biologic Therapy
0
0.73
Genomic Medicine
0
0.69
Genetics
0
0.57
Leukemia
0
0.45
Toxicology
0
0.42
Cancer
0
0.29
Neutropenia
0
0.27
Adverse Effects
0
0.14
Arthralgia
0
0.14
Clinical Research
0
0.14
Diarrhea
0
0.14
Grant
0
0.14
Healthcare and Medical Technology
0
0.14
Hypertension
0
0.14
Immunoglobulin A (IgA)
0
0.14
Nausea
0
0.14
New York
0
0.14
Patient Safety
0
0.14
Remission
0
0.14
Residual Disease
0
0.14
Specialty
Lead
score
Hematology-Oncology
1
1
Pharmacist
0
0.9
Edit Tags